Orthopedic Robots: What Enovis Bought With eCential Robotics

Enovis is filling one of the biggest gaps in its reconstructive portfolio.

On September 1, the company made a binding offer to acquire LSI Alumni company eCential Robotics for €155 million upfront, plus up to €35 million in potential milestones. That works out to roughly $180 million at closing and as much as €190 million in total consideration. The transaction is expected to close during the fourth quarter of 2026, subject to regulatory approvals.

For Enovis, the acquisition provides a path into orthopedic robots. But eCential brings something more unusual than a single robotic system. It has spent years building technology for other orthopedic companies, including some that will soon compete directly with its new owner.

The Numbers Behind the Deal

eCential was founded in 2009 and raised approximately €100 million through equity, quasi-equity, and debt in January 2021. Across six rounds, the company raised roughly $110 million over its lifetime.

Enovis is now offering €155 million upfront, with the potential for the transaction to reach €190 million.

The price also looks familiar.

Zimmer Biomet acquired Monogram Technologies for $177 million in July 2025. 14 months later, Enovis agreed to pay roughly $180 million upfront for eCential. The two independent robotics companies landed within about 2% of each other.

Meanwhile, the scale of the established competition continues to grow. Stryker had installed 3,000 Mako systems by year-end 2025. More than two-thirds of its U.S. knee procedures and more than one-third of its U.S. hip procedures use Mako, while more than half of knee procedures globally are now robot-assisted.

Enovis expects its own knee robot to launch in late 2028, followed by a shoulder system in 2029, with initial commercial contribution beginning in 2028.

Enovis guides to $2.31 billion to $2.37 billion in 2026 revenue. Q2 revenue reached $582.8 million, up 3% reported. The stock fell about 9% on that print on August 6. Four weeks later, management committed $180 million to a product that ships in 26 months.

What Enovis Gets With eCential

The unusual part of the acquisition is eCential’s position as an implant-agnostic robotics company.

At LSI USA ’26, CEO Clément Vidal described the company simply: “We are not an implant manufacturer; our platform is implant agnostic.”

That approach created several businesses. eCential developed the VELYS Spine robot for J&J MedTech’s DePuy Synthes “from specification to FDA clearance on behalf of J&J,” according to Vidal. VELYS Spine received FDA clearance in 2024, launched commercially in the first half of 2025, and surpassed 600 cases by March 2026.

eCential also supplies its robotic platform through a non-exclusive OEM agreement for Amplitude Surgical’s Andy knee robot, which received CE marking in November 2025. Amplitude is now owned by India-based Zydus Lifesciences.

Then there is eCential’s own Op.n platform, an implant-agnostic system that recently received FDA clearance and entered a limited U.S. release.

Enovis has said it intends to maintain eCential’s existing partnerships and establish a robotics center of excellence in Grenoble. It also says it does not plan to enter surgical spine. Its own robotics roadmap instead begins with total knee and moves into total shoulder.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/orthopedic-robots-what-enovis-bought-with-ecential-robotics